James Marsh
Concepts (510)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardium | 46 | 2008 | 453 | 2.340 |
Why?
| | Calcium Channels, L-Type | 17 | 2008 | 69 | 1.810 |
Why?
| | Myocardial Contraction | 35 | 2010 | 112 | 1.340 |
Why?
| | Calcium | 32 | 2017 | 376 | 0.950 |
Why?
| | Platelet Aggregation Inhibitors | 4 | 2017 | 181 | 0.910 |
Why?
| | Stroke | 3 | 2019 | 512 | 0.870 |
Why?
| | Calcium Channels | 11 | 2006 | 42 | 0.850 |
Why?
| | Genetic Therapy | 3 | 2009 | 121 | 0.830 |
Why?
| | Platelet Function Tests | 2 | 2013 | 17 | 0.800 |
Why?
| | Blood Platelets | 3 | 2017 | 259 | 0.780 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2013 | 29 | 0.770 |
Why?
| | Rats | 37 | 2010 | 3220 | 0.740 |
Why?
| | Ion Channels | 9 | 2009 | 70 | 0.720 |
Why?
| | Myocytes, Cardiac | 8 | 2010 | 129 | 0.670 |
Why?
| | Coronary Disease | 6 | 2004 | 152 | 0.670 |
Why?
| | Brain Ischemia | 2 | 2019 | 161 | 0.640 |
Why?
| | Heart | 16 | 2002 | 345 | 0.620 |
Why?
| | Fluorocarbons | 1 | 2019 | 61 | 0.600 |
Why?
| | Biomedical Research | 3 | 2018 | 256 | 0.600 |
Why?
| | Neuroprotective Agents | 1 | 2019 | 101 | 0.590 |
Why?
| | Research Personnel | 2 | 2018 | 71 | 0.580 |
Why?
| | Cells, Cultured | 39 | 2008 | 1567 | 0.580 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2006 | 133 | 0.570 |
Why?
| | Receptors, Adrenergic, beta | 11 | 2000 | 43 | 0.570 |
Why?
| | Animals | 68 | 2012 | 13505 | 0.570 |
Why?
| | Personnel Selection | 1 | 2017 | 24 | 0.560 |
Why?
| | Internal Medicine | 1 | 2017 | 19 | 0.560 |
Why?
| | Cardiovascular Diseases | 4 | 2020 | 490 | 0.530 |
Why?
| | Leadership | 1 | 2017 | 103 | 0.530 |
Why?
| | Faculty, Medical | 1 | 2017 | 91 | 0.530 |
Why?
| | Heart Ventricles | 20 | 2010 | 267 | 0.530 |
Why?
| | Isoproterenol | 14 | 2002 | 55 | 0.460 |
Why?
| | Physician's Role | 1 | 2014 | 49 | 0.450 |
Why?
| | Sodium-Calcium Exchanger | 6 | 2004 | 8 | 0.440 |
Why?
| | RNA, Messenger | 17 | 2005 | 1132 | 0.420 |
Why?
| | Education, Medical | 1 | 2014 | 111 | 0.410 |
Why?
| | Chest Pain | 1 | 2013 | 57 | 0.410 |
Why?
| | Rats, Sprague-Dawley | 20 | 2005 | 1563 | 0.410 |
Why?
| | Ticlopidine | 1 | 2013 | 56 | 0.400 |
Why?
| | Coronary Artery Disease | 3 | 2012 | 294 | 0.380 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 2012 | 136 | 0.380 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2010 | 145 | 0.360 |
Why?
| | Acute Coronary Syndrome | 1 | 2012 | 80 | 0.350 |
Why?
| | Transcription, Genetic | 6 | 2002 | 378 | 0.350 |
Why?
| | Excitation Contraction Coupling | 1 | 2010 | 3 | 0.340 |
Why?
| | Calcium Signaling | 1 | 2010 | 51 | 0.340 |
Why?
| | Cardiomegaly | 3 | 1998 | 38 | 0.320 |
Why?
| | Calcium Channel Blockers | 7 | 1997 | 60 | 0.320 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 467 | 0.310 |
Why?
| | Hypertension | 5 | 2020 | 565 | 0.310 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 522 | 0.310 |
Why?
| | Protein Subunits | 4 | 2008 | 79 | 0.300 |
Why?
| | Chick Embryo | 23 | 1993 | 81 | 0.290 |
Why?
| | Norepinephrine | 4 | 2002 | 112 | 0.290 |
Why?
| | Molecular Mimicry | 1 | 2008 | 38 | 0.290 |
Why?
| | Troponin I | 1 | 2008 | 18 | 0.280 |
Why?
| | Sarcoplasmic Reticulum | 4 | 2010 | 22 | 0.280 |
Why?
| | Drug Design | 1 | 2008 | 120 | 0.270 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2008 | 60 | 0.270 |
Why?
| | Humans | 33 | 2020 | 52483 | 0.270 |
Why?
| | Time Factors | 9 | 2019 | 2968 | 0.260 |
Why?
| | Male | 31 | 2019 | 26761 | 0.250 |
Why?
| | Muscle Proteins | 5 | 2007 | 321 | 0.240 |
Why?
| | RNA Splice Sites | 1 | 2005 | 10 | 0.230 |
Why?
| | Arteriosclerosis | 1 | 2004 | 53 | 0.230 |
Why?
| | Testosterone | 6 | 2005 | 141 | 0.230 |
Why?
| | Alternative Splicing | 1 | 2005 | 62 | 0.230 |
Why?
| | Stents | 3 | 2013 | 351 | 0.220 |
Why?
| | Receptors, Adrenergic | 2 | 2001 | 14 | 0.220 |
Why?
| | Ventricular Function | 7 | 2005 | 19 | 0.220 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 944 | 0.220 |
Why?
| | Mutation | 2 | 2008 | 1347 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 129 | 0.220 |
Why?
| | United States | 7 | 2018 | 5192 | 0.210 |
Why?
| | Adrenergic beta-Agonists | 6 | 2001 | 42 | 0.210 |
Why?
| | Receptors, Androgen | 3 | 2005 | 46 | 0.210 |
Why?
| | Gene Expression Regulation | 6 | 2006 | 990 | 0.210 |
Why?
| | Muscle Cells | 1 | 2003 | 22 | 0.200 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2002 | 16 | 0.200 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2001 | 63 | 0.200 |
Why?
| | Apoptosis | 2 | 2005 | 1119 | 0.200 |
Why?
| | Glucose | 1 | 2005 | 355 | 0.200 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 33 | 0.200 |
Why?
| | Cell Membrane | 4 | 2017 | 245 | 0.190 |
Why?
| | Risk Factors | 6 | 2020 | 3889 | 0.190 |
Why?
| | Muscle Contraction | 1 | 2003 | 117 | 0.190 |
Why?
| | Vasoconstrictor Agents | 1 | 2002 | 82 | 0.180 |
Why?
| | Peptides | 1 | 2002 | 223 | 0.180 |
Why?
| | Treatment Outcome | 4 | 2019 | 5422 | 0.180 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 395 | 0.180 |
Why?
| | Female | 18 | 2019 | 28171 | 0.170 |
Why?
| | Estrogens, Non-Steroidal | 1 | 2000 | 15 | 0.170 |
Why?
| | 5' Untranslated Regions | 1 | 2000 | 30 | 0.170 |
Why?
| | Plants | 1 | 2000 | 30 | 0.170 |
Why?
| | Kinetics | 9 | 2010 | 626 | 0.170 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2001 | 20 | 0.160 |
Why?
| | Phenylephrine | 4 | 2001 | 34 | 0.160 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 39 | 0.160 |
Why?
| | Isoflavones | 1 | 2000 | 88 | 0.160 |
Why?
| | Sulfonamides | 1 | 2000 | 133 | 0.160 |
Why?
| | Orchiectomy | 3 | 2004 | 38 | 0.160 |
Why?
| | Administration, Intravenous | 1 | 2019 | 73 | 0.160 |
Why?
| | Sex Factors | 2 | 2013 | 727 | 0.160 |
Why?
| | Multivariate Analysis | 2 | 2013 | 591 | 0.160 |
Why?
| | Angiotensin II | 3 | 1999 | 162 | 0.160 |
Why?
| | Disability Evaluation | 1 | 2019 | 92 | 0.160 |
Why?
| | Nitric Oxide Donors | 1 | 1998 | 9 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 374 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2002 | 481 | 0.150 |
Why?
| | Recovery of Function | 1 | 2019 | 199 | 0.150 |
Why?
| | Genetic Vectors | 2 | 2009 | 128 | 0.150 |
Why?
| | Middle Aged | 10 | 2019 | 13028 | 0.150 |
Why?
| | Base Sequence | 4 | 2005 | 640 | 0.140 |
Why?
| | Logistic Models | 2 | 2013 | 925 | 0.140 |
Why?
| | Animals, Newborn | 7 | 2007 | 362 | 0.140 |
Why?
| | Risk Assessment | 2 | 2013 | 1327 | 0.140 |
Why?
| | Women | 1 | 2017 | 30 | 0.140 |
Why?
| | Double-Blind Method | 1 | 2019 | 713 | 0.140 |
Why?
| | Schools, Medical | 1 | 2017 | 69 | 0.140 |
Why?
| | Mitochondria, Heart | 4 | 2005 | 37 | 0.140 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 5 | 1993 | 9 | 0.130 |
Why?
| | Blotting, Northern | 3 | 2002 | 106 | 0.130 |
Why?
| | Platelet Activation | 1 | 2017 | 47 | 0.130 |
Why?
| | Signal Transduction | 3 | 2017 | 1671 | 0.130 |
Why?
| | Nitric Oxide | 1 | 1998 | 249 | 0.130 |
Why?
| | Epinephrine | 1 | 2017 | 97 | 0.130 |
Why?
| | Endothelium, Vascular | 3 | 2004 | 246 | 0.130 |
Why?
| | Minority Groups | 1 | 2017 | 135 | 0.130 |
Why?
| | Serotonin | 1 | 2017 | 146 | 0.130 |
Why?
| | Receptors, Cholinergic | 1 | 1996 | 14 | 0.130 |
Why?
| | Down-Regulation | 2 | 2008 | 346 | 0.130 |
Why?
| | Catecholamines | 3 | 1996 | 44 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 219 | 0.120 |
Why?
| | Algorithms | 3 | 2013 | 672 | 0.120 |
Why?
| | Cardiotonic Agents | 2 | 2010 | 82 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 1999 | 412 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 1996 | 137 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2008 | 93 | 0.120 |
Why?
| | Thrombolytic Therapy | 2 | 2010 | 110 | 0.120 |
Why?
| | Ribonucleosides | 1 | 1994 | 2 | 0.120 |
Why?
| | Aminoimidazole Carboxamide | 1 | 1994 | 2 | 0.120 |
Why?
| | Protein Isoforms | 3 | 2007 | 123 | 0.110 |
Why?
| | Physicians | 1 | 2018 | 241 | 0.110 |
Why?
| | Bradykinin | 3 | 1999 | 16 | 0.110 |
Why?
| | DNA, Complementary | 2 | 2008 | 135 | 0.110 |
Why?
| | Age Factors | 2 | 2013 | 1132 | 0.110 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1994 | 48 | 0.110 |
Why?
| | Gene Expression | 5 | 2003 | 618 | 0.110 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2004 | 7 | 0.110 |
Why?
| | Cyclic AMP | 5 | 2000 | 91 | 0.110 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2013 | 13 | 0.110 |
Why?
| | Blood Pressure | 3 | 2006 | 537 | 0.100 |
Why?
| | Dihydropyridines | 3 | 1993 | 7 | 0.100 |
Why?
| | Smoking | 1 | 2017 | 520 | 0.100 |
Why?
| | Arkansas | 1 | 2019 | 2028 | 0.100 |
Why?
| | Educational Measurement | 1 | 2014 | 196 | 0.100 |
Why?
| | NAD | 2 | 2002 | 45 | 0.100 |
Why?
| | Therapy, Computer-Assisted | 1 | 2013 | 31 | 0.100 |
Why?
| | Drug Resistance | 1 | 2013 | 65 | 0.100 |
Why?
| | Calsequestrin | 3 | 2007 | 3 | 0.100 |
Why?
| | Tachycardia, Ventricular | 1 | 2013 | 46 | 0.100 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 37 | 0.100 |
Why?
| | Cell Line | 2 | 2008 | 1030 | 0.100 |
Why?
| | Beriberi | 1 | 2012 | 5 | 0.100 |
Why?
| | Ganglia, Sympathetic | 1 | 1992 | 3 | 0.100 |
Why?
| | Defibrillators, Implantable | 1 | 2013 | 69 | 0.090 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 1988 | 24 | 0.090 |
Why?
| | Binding Sites | 5 | 2002 | 377 | 0.090 |
Why?
| | Lipoproteins, LDL | 3 | 2004 | 169 | 0.090 |
Why?
| | Cell Communication | 1 | 1992 | 71 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2012 | 83 | 0.090 |
Why?
| | Protein Kinase C | 2 | 2002 | 68 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2012 | 70 | 0.090 |
Why?
| | Odds Ratio | 1 | 2013 | 558 | 0.090 |
Why?
| | Electrocardiography | 1 | 2013 | 268 | 0.090 |
Why?
| | Immunoblotting | 2 | 2002 | 116 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2002 | 778 | 0.090 |
Why?
| | Incidence | 2 | 2008 | 1062 | 0.090 |
Why?
| | International Normalized Ratio | 1 | 2010 | 28 | 0.090 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 50 | 0.090 |
Why?
| | Diabetic Angiopathies | 1 | 2010 | 23 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 261 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2010 | 43 | 0.090 |
Why?
| | Cardiomyopathies | 3 | 2002 | 121 | 0.080 |
Why?
| | Intracranial Hemorrhages | 1 | 2010 | 39 | 0.080 |
Why?
| | Foramen Ovale, Patent | 1 | 2010 | 31 | 0.080 |
Why?
| | Endarterectomy, Carotid | 1 | 2010 | 62 | 0.080 |
Why?
| | Adenoviridae | 3 | 2007 | 47 | 0.080 |
Why?
| | Action Potentials | 1 | 2010 | 120 | 0.080 |
Why?
| | Thrombectomy | 1 | 2010 | 72 | 0.080 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2000 | 3 | 0.080 |
Why?
| | Aged | 5 | 2013 | 10121 | 0.080 |
Why?
| | Warfarin | 1 | 2010 | 84 | 0.080 |
Why?
| | Gene Transfer Techniques | 1 | 2009 | 40 | 0.080 |
Why?
| | Gene Targeting | 1 | 2009 | 31 | 0.080 |
Why?
| | Drug Prescriptions | 1 | 2010 | 102 | 0.080 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2013 | 307 | 0.080 |
Why?
| | Prognosis | 2 | 2008 | 2099 | 0.080 |
Why?
| | Protein Modification, Translational | 1 | 2007 | 3 | 0.070 |
Why?
| | Protein Engineering | 1 | 2008 | 20 | 0.070 |
Why?
| | Nifedipine | 4 | 1990 | 25 | 0.070 |
Why?
| | Glasgow Coma Scale | 1 | 2008 | 45 | 0.070 |
Why?
| | Rats, Inbred WKY | 1 | 2008 | 34 | 0.070 |
Why?
| | Spectrometry, Fluorescence | 2 | 2002 | 46 | 0.070 |
Why?
| | Rats, Inbred SHR | 1 | 2008 | 42 | 0.070 |
Why?
| | Heart Diseases | 1 | 2010 | 216 | 0.070 |
Why?
| | Atrial Fibrillation | 1 | 2010 | 200 | 0.070 |
Why?
| | Acidosis | 1 | 1988 | 41 | 0.070 |
Why?
| | Cerebrovascular Disorders | 1 | 2008 | 48 | 0.070 |
Why?
| | Mesenteric Arteries | 1 | 2008 | 43 | 0.070 |
Why?
| | Medical Records | 1 | 2008 | 87 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2008 | 84 | 0.070 |
Why?
| | Triiodothyronine | 1 | 1987 | 28 | 0.070 |
Why?
| | Anticoagulants | 1 | 2010 | 270 | 0.070 |
Why?
| | Homeostasis | 4 | 2002 | 201 | 0.070 |
Why?
| | Thrombosis | 1 | 2010 | 253 | 0.070 |
Why?
| | Oxadiazoles | 1 | 1987 | 9 | 0.070 |
Why?
| | Cell Culture Techniques | 2 | 2005 | 102 | 0.070 |
Why?
| | Cholesterol | 1 | 2008 | 153 | 0.070 |
Why?
| | Heart Rate | 3 | 2001 | 318 | 0.070 |
Why?
| | Dogs | 3 | 2007 | 180 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 177 | 0.070 |
Why?
| | Cerebral Hemorrhage | 1 | 2008 | 97 | 0.070 |
Why?
| | Propranolol | 3 | 1994 | 78 | 0.070 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 117 | 0.070 |
Why?
| | Prospective Studies | 1 | 2013 | 2481 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2017 | 110 | 0.070 |
Why?
| | Pyridones | 1 | 1987 | 36 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 560 | 0.070 |
Why?
| | Aorta | 2 | 2005 | 165 | 0.070 |
Why?
| | 1-Methyl-3-isobutylxanthine | 4 | 1998 | 8 | 0.060 |
Why?
| | Verapamil | 5 | 1994 | 20 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 1987 | 96 | 0.060 |
Why?
| | Angina Pectoris | 1 | 1986 | 19 | 0.060 |
Why?
| | Adult | 9 | 2017 | 14161 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 154 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2007 | 313 | 0.060 |
Why?
| | Arteriovenous Fistula | 1 | 1986 | 28 | 0.060 |
Why?
| | Aortic Aneurysm | 1 | 1986 | 28 | 0.060 |
Why?
| | Carotid Stenosis | 1 | 2006 | 66 | 0.060 |
Why?
| | Vena Cava, Inferior | 1 | 1986 | 65 | 0.060 |
Why?
| | Hospital Mortality | 1 | 2008 | 435 | 0.060 |
Why?
| | Aortic Diseases | 1 | 1986 | 54 | 0.060 |
Why?
| | Cytoskeleton | 1 | 1985 | 39 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 1985 | 48 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2005 | 15 | 0.060 |
Why?
| | Mannitol | 1 | 2005 | 15 | 0.060 |
Why?
| | Alprenolol | 1 | 1985 | 1 | 0.060 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2005 | 21 | 0.060 |
Why?
| | Restriction Mapping | 1 | 2005 | 33 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 121 | 0.060 |
Why?
| | Tumor Necrosis Factors | 1 | 2004 | 8 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 1 | 2005 | 53 | 0.060 |
Why?
| | Casein Kinase II | 1 | 2004 | 10 | 0.060 |
Why?
| | Muscle, Smooth | 1 | 2004 | 64 | 0.060 |
Why?
| | DNA Primers | 1 | 2005 | 208 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2005 | 190 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2005 | 171 | 0.060 |
Why?
| | bcl-X Protein | 1 | 2005 | 54 | 0.060 |
Why?
| | Myosin Heavy Chains | 1 | 2004 | 25 | 0.060 |
Why?
| | Coronary Artery Bypass | 2 | 2010 | 125 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 242 | 0.060 |
Why?
| | Ligands | 1 | 2004 | 206 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 34 | 0.050 |
Why?
| | Antihypertensive Agents | 2 | 2020 | 132 | 0.050 |
Why?
| | Pyridines | 1 | 1985 | 132 | 0.050 |
Why?
| | Calcium Radioisotopes | 3 | 1989 | 7 | 0.050 |
Why?
| | Gonadal Steroid Hormones | 2 | 2003 | 39 | 0.050 |
Why?
| | Androgens | 1 | 2004 | 70 | 0.050 |
Why?
| | Temperature | 1 | 2004 | 183 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 582 | 0.050 |
Why?
| | Angiography | 1 | 1983 | 114 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 1046 | 0.050 |
Why?
| | Ion Channel Gating | 2 | 2006 | 33 | 0.050 |
Why?
| | DNA Footprinting | 1 | 2002 | 9 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2003 | 54 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2002 | 8 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2003 | 93 | 0.050 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2002 | 42 | 0.050 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2002 | 74 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2003 | 144 | 0.050 |
Why?
| | Pulmonary Embolism | 1 | 1983 | 86 | 0.050 |
Why?
| | Vasodilation | 1 | 2003 | 99 | 0.050 |
Why?
| | Cardiac Pacing, Artificial | 2 | 1994 | 34 | 0.050 |
Why?
| | Proteins | 1 | 2005 | 348 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 151 | 0.050 |
Why?
| | Receptors, Nicotinic | 2 | 1992 | 73 | 0.050 |
Why?
| | Macrophages | 1 | 2004 | 379 | 0.050 |
Why?
| | Lovastatin | 2 | 1993 | 9 | 0.050 |
Why?
| | Acute Disease | 1 | 2002 | 373 | 0.050 |
Why?
| | Blotting, Western | 1 | 2003 | 590 | 0.050 |
Why?
| | Systole | 2 | 1990 | 72 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2002 | 461 | 0.050 |
Why?
| | Phenylalanine | 2 | 1999 | 132 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 372 | 0.050 |
Why?
| | Electrophysiology | 3 | 1996 | 68 | 0.040 |
Why?
| | Chronotherapy | 1 | 2020 | 2 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2002 | 150 | 0.040 |
Why?
| | Hemorrhage | 1 | 2002 | 209 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2002 | 245 | 0.040 |
Why?
| | Isoquinolines | 1 | 2000 | 24 | 0.040 |
Why?
| | Biological Transport | 1 | 2001 | 160 | 0.040 |
Why?
| | Electrophoresis | 1 | 2000 | 16 | 0.040 |
Why?
| | Phytoestrogens | 1 | 2000 | 23 | 0.040 |
Why?
| | Inflammation | 1 | 2004 | 641 | 0.040 |
Why?
| | RNA, Antisense | 1 | 2000 | 6 | 0.040 |
Why?
| | Genetic Complementation Test | 1 | 2000 | 47 | 0.040 |
Why?
| | Up-Regulation | 3 | 2017 | 454 | 0.040 |
Why?
| | Luciferases | 1 | 2000 | 48 | 0.040 |
Why?
| | Plant Preparations | 1 | 2000 | 41 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2002 | 467 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2000 | 88 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 96 | 0.040 |
Why?
| | Stimulation, Chemical | 3 | 1990 | 27 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2000 | 187 | 0.040 |
Why?
| | Decision Trees | 1 | 1999 | 22 | 0.040 |
Why?
| | Lung | 1 | 1983 | 509 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 1999 | 8 | 0.040 |
Why?
| | Transfection | 1 | 2000 | 357 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 1979 | 92 | 0.040 |
Why?
| | Transcription Factors | 1 | 2002 | 566 | 0.040 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 2 | 1993 | 60 | 0.040 |
Why?
| | omega-N-Methylarginine | 1 | 1998 | 3 | 0.040 |
Why?
| | Iloprost | 1 | 1998 | 4 | 0.040 |
Why?
| | Molsidomine | 1 | 1998 | 5 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1998 | 16 | 0.040 |
Why?
| | Nitroprusside | 1 | 1998 | 11 | 0.040 |
Why?
| | Indomethacin | 1 | 1998 | 35 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 11 | 0.040 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1998 | 42 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2018 | 44 | 0.040 |
Why?
| | Propanolamines | 2 | 1988 | 14 | 0.040 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.030 |
Why?
| | Transglutaminases | 1 | 2017 | 14 | 0.030 |
Why?
| | Patch-Clamp Techniques | 1 | 1997 | 111 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 64 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 72 | 0.030 |
Why?
| | Polysaccharides | 1 | 2017 | 57 | 0.030 |
Why?
| | Cell Division | 3 | 2003 | 291 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 180 | 0.030 |
Why?
| | Heart Failure | 2 | 1993 | 565 | 0.030 |
Why?
| | Cell Movement | 2 | 2003 | 268 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 1998 | 258 | 0.030 |
Why?
| | Enkephalins | 2 | 1986 | 5 | 0.030 |
Why?
| | Glycosylation | 2 | 2007 | 106 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 339 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 251 | 0.030 |
Why?
| | Pindolol | 2 | 1985 | 4 | 0.030 |
Why?
| | GTP-Binding Proteins | 2 | 1993 | 85 | 0.030 |
Why?
| | Extracellular Space | 2 | 1993 | 37 | 0.030 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1994 | 2 | 0.030 |
Why?
| | Curriculum | 1 | 2018 | 398 | 0.030 |
Why?
| | Theophylline | 1 | 1994 | 17 | 0.030 |
Why?
| | Osmolar Concentration | 2 | 1991 | 62 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 1994 | 138 | 0.030 |
Why?
| | Caspases | 2 | 2005 | 104 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2017 | 1201 | 0.030 |
Why?
| | Phosphorylation | 2 | 2005 | 528 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 1988 | 1378 | 0.030 |
Why?
| | Cell Separation | 3 | 2005 | 83 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1993 | 40 | 0.030 |
Why?
| | Receptors, Drug | 1 | 1993 | 4 | 0.030 |
Why?
| | Digoxin | 1 | 1993 | 29 | 0.030 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 46 | 0.030 |
Why?
| | Internship and Residency | 1 | 2018 | 448 | 0.020 |
Why?
| | Isradipine | 2 | 1993 | 4 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 1994 | 1478 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 57 | 0.020 |
Why?
| | Ouabain | 3 | 1993 | 28 | 0.020 |
Why?
| | Potassium | 3 | 1993 | 58 | 0.020 |
Why?
| | Adenine Nucleotides | 1 | 1991 | 3 | 0.020 |
Why?
| | Cyanides | 1 | 1991 | 5 | 0.020 |
Why?
| | Potassium Chloride | 1 | 1991 | 19 | 0.020 |
Why?
| | Electron Transport | 1 | 1991 | 26 | 0.020 |
Why?
| | Lactates | 1 | 1991 | 31 | 0.020 |
Why?
| | Cricetinae | 3 | 2002 | 194 | 0.020 |
Why?
| | Deoxyglucose | 1 | 1991 | 35 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1991 | 187 | 0.020 |
Why?
| | Aorta, Abdominal | 2 | 1994 | 39 | 0.020 |
Why?
| | Malnutrition | 1 | 2012 | 90 | 0.020 |
Why?
| | Fluoresceins | 1 | 1990 | 11 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 891 | 0.020 |
Why?
| | Benzofurans | 1 | 1990 | 18 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 1991 | 205 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1991 | 326 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 1990 | 22 | 0.020 |
Why?
| | Phenethylamines | 1 | 1989 | 8 | 0.020 |
Why?
| | Hospitals, Veterans | 1 | 2010 | 110 | 0.020 |
Why?
| | Infant | 1 | 1998 | 3733 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 78 | 0.020 |
Why?
| | Cardiac Catheterization | 2 | 1983 | 232 | 0.020 |
Why?
| | Tritium | 2 | 1993 | 45 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 1229 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 1989 | 10 | 0.020 |
Why?
| | Sodium Channels | 1 | 1989 | 11 | 0.020 |
Why?
| | Depression, Chemical | 1 | 1988 | 13 | 0.020 |
Why?
| | Bupivacaine | 1 | 1989 | 30 | 0.020 |
Why?
| | Aspirin | 1 | 2010 | 115 | 0.020 |
Why?
| | Lidocaine | 1 | 1989 | 46 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1991 | 302 | 0.020 |
Why?
| | Culture Media | 2 | 1993 | 98 | 0.020 |
Why?
| | Amiloride | 1 | 1988 | 7 | 0.020 |
Why?
| | Aerobiosis | 1 | 1988 | 13 | 0.020 |
Why?
| | Oxygen | 2 | 1982 | 336 | 0.020 |
Why?
| | Anaerobiosis | 1 | 1988 | 20 | 0.020 |
Why?
| | Free Radicals | 1 | 1988 | 28 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1993 | 367 | 0.020 |
Why?
| | Catalase | 1 | 1988 | 73 | 0.020 |
Why?
| | Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 2007 | 1 | 0.020 |
Why?
| | Leupeptins | 1 | 2007 | 5 | 0.020 |
Why?
| | Tunicamycin | 1 | 2007 | 11 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2007 | 21 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 1988 | 119 | 0.020 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2007 | 15 | 0.020 |
Why?
| | COS Cells | 1 | 2007 | 73 | 0.020 |
Why?
| | Cell Membrane Permeability | 2 | 1987 | 25 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1988 | 178 | 0.020 |
Why?
| | Sarcolemma | 1 | 1987 | 3 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 610 | 0.020 |
Why?
| | Radioligand Assay | 1 | 1987 | 46 | 0.020 |
Why?
| | Milrinone | 1 | 1987 | 9 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2007 | 134 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2007 | 104 | 0.020 |
Why?
| | Binding, Competitive | 1 | 1987 | 90 | 0.020 |
Why?
| | Pulmonary Circulation | 2 | 1983 | 29 | 0.020 |
Why?
| | Phenotype | 2 | 2003 | 789 | 0.020 |
Why?
| | Caspase 8 | 1 | 2005 | 10 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2005 | 15 | 0.020 |
Why?
| | Cats | 1 | 2005 | 73 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2006 | 109 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 288 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2005 | 58 | 0.020 |
Why?
| | bcl-2 Homologous Antagonist-Killer Protein | 1 | 2005 | 21 | 0.020 |
Why?
| | Protein Conformation | 1 | 2006 | 176 | 0.020 |
Why?
| | Heart Neoplasms | 1 | 1985 | 32 | 0.020 |
Why?
| | Testosterone Propionate | 1 | 2005 | 1 | 0.010 |
Why?
| | Guanylyl Imidodiphosphate | 1 | 1985 | 1 | 0.010 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2004 | 17 | 0.010 |
Why?
| | Phosphates | 1 | 2004 | 49 | 0.010 |
Why?
| | Carcinoma | 1 | 1985 | 138 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 1985 | 116 | 0.010 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1983 | 4 | 0.010 |
Why?
| | Nitrendipine | 1 | 1983 | 2 | 0.010 |
Why?
| | Diltiazem | 1 | 1983 | 10 | 0.010 |
Why?
| | Echocardiography | 2 | 1993 | 415 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 105 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1983 | 107 | 0.010 |
Why?
| | Pressure | 1 | 2003 | 104 | 0.010 |
Why?
| | Ion Exchange | 1 | 2002 | 1 | 0.010 |
Why?
| | Risk | 1 | 1983 | 316 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2004 | 198 | 0.010 |
Why?
| | Organ Size | 1 | 2002 | 228 | 0.010 |
Why?
| | Hemodynamics | 1 | 1983 | 263 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 270 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 807 | 0.010 |
Why?
| | Heart Atria | 2 | 1993 | 63 | 0.010 |
Why?
| | Dihydroalprenolol | 1 | 1980 | 3 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2013 | 6607 | 0.010 |
Why?
| | Chronic Disease | 1 | 2003 | 586 | 0.010 |
Why?
| | Sodium | 3 | 1987 | 95 | 0.010 |
Why?
| | Pulse | 1 | 1979 | 13 | 0.010 |
Why?
| | Oximetry | 1 | 1980 | 66 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 735 | 0.010 |
Why?
| | Carotid Arteries | 1 | 1979 | 77 | 0.010 |
Why?
| | Flavonoids | 1 | 1999 | 54 | 0.010 |
Why?
| | Sirolimus | 1 | 1999 | 65 | 0.010 |
Why?
| | Endothelium | 1 | 1998 | 37 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1983 | 1068 | 0.010 |
Why?
| | Naloxone | 2 | 1986 | 79 | 0.010 |
Why?
| | Prazosin | 1 | 1994 | 10 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1994 | 25 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1994 | 47 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 91 | 0.010 |
Why?
| | Turkeys | 1 | 1993 | 10 | 0.010 |
Why?
| | Computers | 1 | 1994 | 48 | 0.010 |
Why?
| | Virulence Factors, Bordetella | 1 | 1993 | 7 | 0.010 |
Why?
| | Pertussis Toxin | 1 | 1993 | 9 | 0.010 |
Why?
| | Neoplasms | 1 | 1983 | 1325 | 0.010 |
Why?
| | Cattle | 1 | 1993 | 205 | 0.010 |
Why?
| | Fetal Blood | 1 | 1993 | 80 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 1992 | 13 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 1993 | 172 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1993 | 554 | 0.010 |
Why?
| | Fibroblasts | 1 | 1994 | 355 | 0.010 |
Why?
| | Stroke Volume | 1 | 1993 | 155 | 0.010 |
Why?
| | Cell Survival | 1 | 1993 | 612 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1992 | 578 | 0.010 |
Why?
| | Mesocricetus | 1 | 1990 | 6 | 0.010 |
Why?
| | Fura-2 | 1 | 1990 | 3 | 0.010 |
Why?
| | Lanthanum | 1 | 1990 | 4 | 0.010 |
Why?
| | Diastole | 1 | 1990 | 70 | 0.010 |
Why?
| | Fluorescence | 1 | 1990 | 39 | 0.010 |
Why?
| | Calibration | 1 | 1990 | 57 | 0.010 |
Why?
| | Reference Values | 1 | 1990 | 313 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1990 | 105 | 0.010 |
Why?
| | Adenosine Diphosphate Ribose | 1 | 1989 | 7 | 0.010 |
Why?
| | Cholera Toxin | 1 | 1989 | 16 | 0.010 |
Why?
| | Atrial Function | 1 | 1989 | 7 | 0.010 |
Why?
| | Oxidative Phosphorylation | 1 | 1987 | 46 | 0.000 |
Why?
| | Glycolysis | 1 | 1987 | 73 | 0.000 |
Why?
| | Enkephalin, Methionine | 1 | 1986 | 3 | 0.000 |
Why?
| | Oxygen Consumption | 1 | 1987 | 198 | 0.000 |
Why?
| | Pulmonary Valve Stenosis | 1 | 1985 | 14 | 0.000 |
Why?
| | Receptors, Opioid | 1 | 1985 | 17 | 0.000 |
Why?
| | Aging | 1 | 1990 | 701 | 0.000 |
Why?
| | Adolescent | 1 | 1992 | 6739 | 0.000 |
Why?
| | Coronary Circulation | 1 | 1980 | 57 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1980 | 109 | 0.000 |
Why?
| | Hemoglobins | 1 | 1980 | 112 | 0.000 |
Why?
| | Brain | 1 | 1985 | 1323 | 0.000 |
Why?
|
|
Marsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|